Publications (34) Carles Iniesta Navalon publications

filter_list

2025

  1. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: “early therapeutic drug monitoring of adalimumab”

    Clinical Rheumatology, Vol. 44, Núm. 3, pp. 1009-1018

  2. Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients

    Gastroenterologia y Hepatologia, Vol. 48, Núm. 6

  3. Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab

    Therapeutic Drug Monitoring, Vol. 47, Núm. 3, pp. 346-352

  4. Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes

    Gastroenterologia y Hepatologia

  5. External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease

    Therapeutic Drug Monitoring

  6. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease

    Revista Espanola de Enfermedades Digestivas, Vol. 117, Núm. 4, pp. 205-212

2024

  1. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 6, pp. 553-561

  2. Therapeutic drug monitoring of inhaled tobramycin in a patient with chronic kidney disease

    European Journal of Hospital Pharmacy

2023

  1. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 7, pp. 504-511

2022

  1. Riesgo de infecciones en pacientes con psoriasis en tratamiento con terapias biológicas (anti il-17 y anti il-23): una revisión sistemática con metaanálisis

    XL Reunión Anual de la Sociedad Española de Epidemiología (SEE) y XVII Congresso da Associação Portuguesa de Epidemiología (APE)

2021

  1. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 2, pp. 110-115

  2. Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 11, pp. 770-775

2020

  1. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease

    International Journal of Clinical Pharmacy, Vol. 42, Núm. 2, pp. 500-507

2019

  1. Incorporation of direct-acting oral anticoagulants to available therapeutic arsenal: Progress adequately?

    Atencion Primaria

  2. Potential and clinical relevant drug-drug interactions among elderly from nursing homes: A multicentre study in Murcia, Spain

    Ciencia e Saude Coletiva, Vol. 24, Núm. 5, pp. 1895-1902

2018

  1. ¿Sobreutilización de corticoides en las exacerbaciones de pacientes con enfermedad pulmonar obstructiva crónica?

    Journal of Negative and No Positive Results: JONNPR, Vol. 3, Núm. 2, pp. 144-145

2016

  1. Effect of drug interactions involving antiretroviral drugs on viral load in HIV population

    European Journal of Hospital Pharmacy , Vol. 23, Núm. 4, pp. 241-243

2015

  1. Identification of potential clinically significant drug interactions in HIV-infected patients: A comprehensive therapeutic approach

    HIV Medicine, Vol. 16, Núm. 5, pp. 273-279

  2. Influence of equation used to estimate the renal function in dosage potentially nephrotoxic drug

    European Journal of Hospital Pharmacy , Vol. 22, Núm. 1, pp. 23-27

2014

  1. Effectiveness of pharmacist intervention in patients with chronic kidney disease

    International Journal of Clinical Pharmacy, Vol. 36, Núm. 5, pp. 896-903